On April 8, 2022 Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo(VivoVec) and induced pluripotent stem cell (iPSC) based immunotherapies for the treatment of solid tumors and hematologic malignancies, reported the presentation of data supporting the use of a synthetic cytokine receptor, the Rapamycin Activated Cytokine Receptor (RACR), to derive synthetic innate lymphoid cells, RACR-induced cytotoxic innate lymphoid cells (RACR-iCILs) (Press release, Umoja Biopharma, APR 8, 2022, View Source [SID1234611702]). The data will be presented in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, held from April 8-13, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Some of the current limitations of cell therapies are the need for lymphodepletion, and repetitive lymphodepletion at that, in addition to the challenge of in vivo expansion," said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja. "Our induced pluripotent stem cell platform seeks to address many of the limitations holding back cell therapy as we know it. By using a synthetic cytokine receptor that can mimic the downstream signaling of the common gamma chain cytokines essential to lymphoid cell differentiation, we are able to create a renewable starting material for scalable manufacturing of synthetic allogeneic chimeric antigen receptor cell products."
On Sunday, April 10th, Samantha O’Hara, Ph.D., Principal Scientist at Umoja Biopharma, will present a poster (Abstract 547) titled "Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics." The data highlights Umoja’s iPSC-based cell therapy platform in which stem cells are engineered ex vivo to express Umoja’s RACR system and a universal adapter-specific TagCAR. The RACR system is intended to be utilized during the manufacturing process where it has the potential to deliver controlled and consistent proliferation and differentiation signals, resulting in the production of a highly pure, induced cytotoxic innate lymphoid cell product. In addition, the RACR system could enable enhanced in vivo engraftment and persistence in the absence of lymphodepleting chemotherapy. The universal adapter-specific TagCAR is designed to enable simultaneous targeting of tumor, tumor stroma, and immunosuppressive cells in the presence of a cocktail of bispecific small molecule adapters, called TumorTags.